Seroprevalence of markers for hepatitis B viral infection

International Journal of Infectious Diseases

Volumn 15, Issue 2, 2011, Pages

  Merrill, Ray M ^a   Hunter, Bradley D ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Endemicity; Hepatitis B virus; Seromarkers; Seroprevalence; WHO regions

Indexed keywords

BIOLOGICAL MARKER; BLOOD GROUP B ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

CHILD; DIAGNOSTIC ACCURACY; ENDEMIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; POPULATION RESEARCH; PREGNANT WOMAN; REVIEW; SEROPREVALENCE; VIRUS INFECTIVITY; WORLD HEALTH ORGANIZATION;

BIOLOGICAL MARKERS; COST OF ILLNESS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; WORLD HEALTH ORGANIZATION;

EID: 79551470591     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.09.005     Document Type: Review

References (24)

1. Robinson W.S. Hepatitis B viruses. General features (human). Encyclopedia of virology 1994, 554-569. Academic Press, London. R.G. Webster, A. Granoff (Eds.).
2. Ganem D., Schneider R.J. Hepadnaviridae: the viruses and their replication. Fields virology 2001, 2923-2969. Lippincott Williams & Wilkins, Philadelphia. 4th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman (Eds.).
3. Robinson W.S. Hepatitis B virus and hepatitis D virus. Principles and practice of infectious diseases 1995, 1406-1439. Churchill Livingstone, New York. 4th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
4. World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services. WHO/V&B/01.31. Geneva: World Health Organization; 2001.
5. World Health Organization. Global Alert and Response. Hepatitis B. Available at: (accessed November 7, 2010). http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html.
6. Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 1997, 43:1500-1506.
7. Hollinger F.B., Liang T.J. Hepatitis B virus. Fields virology 2001, 2971-3036. Lippincott Williams & Wilkins, Philadelphia. 4th ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman (Eds.).
8. Mahoney F.J., Kane M. Hepatitis B vaccine. Vaccines 1999, 158-182. W.B. Saunders Company, Philadelphia. 3rd ed. S.A. Plotkin, W.A. Orenstein (Eds.).
9. World Health Organization. Hepatitis B. Who is most at risk for chronic disease? Available at: (accessed November 8, 2010). http://www.who.int/mediacentre/factsheets/fs204/en/.
10. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep 1991; 40(RR-13):1-19.
11. Ganem D., Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
12. Lok A.S.F., McMahon B.J. Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
13. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-816.
14. Piccolo P., Lenci I., Demelia L., Bandiera F., Piras M.R., Antonucci G., et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009, 14:1165-1174.
15. Matthews S.J. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther 2006, 28:184-203.
16. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
17. Woo G., Tomlinson G., Nishikawa Y., Kowgier M., Sherman M., Wong D.K., et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010, 139:1218-1229.
18. Cohen C., Evans A.A., London W.T., Block J., Conti M., Block T. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat 2008, 15:12-13.
19. Knorr B., Maul H., Schnitzler P. Prevalence of hepatitis B virus infection among women at reproductive age at a German university hospital. J Clin Virol 2008, 42:422-424.
20. Mohandas K.M., Hepatitis B associated hepatocellular carcinoma: epidemiology, diagnosis and treatment. Hepatitis B Annual 2004, 1:140-152.
21. Zuckerman A.J. Hepatitis viruses. Medical microbiology 1996, 849-863. The University of Texas Medical Branch at Galveston, Galveston. 4th ed. S. Baron (Ed.).
22. Custer B., Sullivan S.D., Hazlet T.K., Iloeje U., Veenstra D.L., Kowdley K.V. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004, 39(10S3):S158-S168.
23. Centers for Disease Control and Prevention. Travelers' health: yellow book. CDC health information for international travel 2008. Chapter 2. Available at: (accessed July 8, 2010). http://www.cdc.gov/travel/yellowBookCh4-HepB.aspx.
24. Lau G., Marcellin P., Peters M. Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies. Hepatol Int 2007, 1:316-325.